These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1846406

  • 1. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer.
    Miles DW, Earl HM, Souhami RL, Harper PG, Rudd R, Ash CM, James L, Trask CW, Tobias JS, Spiro SG.
    J Clin Oncol; 1991 Feb; 9(2):280-5. PubMed ID: 1846406
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 4. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL, Rudd R, Ruiz de Elvira MC, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C.
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [Abstract] [Full Text] [Related]

  • 6. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R.
    Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
    [Abstract] [Full Text] [Related]

  • 7. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    Smith IE, Perren TJ, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, Ford HT.
    J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
    [Abstract] [Full Text] [Related]

  • 8. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T.
    Cancer; 1993 Sep 01; 72(5):1597-601. PubMed ID: 8394202
    [Abstract] [Full Text] [Related]

  • 9. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG.
    J Clin Oncol; 1994 Jan 01; 12(1):77-82. PubMed ID: 7505809
    [Abstract] [Full Text] [Related]

  • 10. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
    Hastürk S, Kurt B, Kocabas A, Orüç O, Burgut R.
    J Chemother; 1997 Feb 01; 9(1):66-71. PubMed ID: 9106021
    [Abstract] [Full Text] [Related]

  • 11. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 01; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 12. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
    Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N.
    J Clin Oncol; 1991 Sep 01; 9(9):1632-8. PubMed ID: 1651995
    [Abstract] [Full Text] [Related]

  • 13. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan 01; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 14. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G.
    Am J Clin Oncol; 1999 Feb 01; 22(1):87-93. PubMed ID: 10025390
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH.
    J Clin Oncol; 1995 Jul 01; 13(7):1615-22. PubMed ID: 7602350
    [Abstract] [Full Text] [Related]

  • 16. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 Jul 01; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 17. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 18. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.
    Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R.
    J Clin Oncol; 1998 May 15; 16(5):1940-7. PubMed ID: 9586913
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK, Stewart D, Logan D, Maroun J, Goss G, Shepherd FA, Latreille J, Warner E, Dahrouge S.
    Semin Oncol; 1992 Dec 15; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [Abstract] [Full Text] [Related]

  • 20. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y, Yamane H, Hiraki A, Harada M.
    Anticancer Res; 1999 Dec 15; 19(1B):693-8. PubMed ID: 10216478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.